REGNRegeneron PharmaceuticalsNot started yet
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
High-Grade Glioma (HGG) · Posterior Fossa-A Ependymoma
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 1/2
- Patients
- 120 (planned)
- Started
- Aug 31, 2026
- Main results expected
- Aug 27, 2032
- Fully finished
- Aug 17, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Measured over: Up to 26 months
Severity of TEAEs
Measured over: Up to 26 months
Overall Survival (OS)
Measured over: 12 months
Progression Free Survival (PFS)
Measured over: 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07567469 · record last updated 2026-05-05 · checked 2026-11-09 15:47 UTC